Skip to main content
. 2021 Jun 23;71(2):327–337. doi: 10.1007/s00262-021-02985-6

Fig. 2.

Fig. 2

Clinical outcomes. (A) Progression-free survival (PFS) based on the use of corticosteroids in the entire cohort, (B) PFS based on the use of corticosteroids in patients with advanced non-small cell lung cancer (NSCLC) and (C) association of the occurrence of immune-related adverse events (irAEs) with PFS in patients with advanced NSCLC